Specialists in the diagnosis
of Alzheimer’s disease
Biocross is developing a series of blood tests for the diagnosis of Alzheimer’s disease, with a view to providing neurologists with an integrated diagnostic solution that can be applied to any disease stage, including the earliest, asymptomatic phase.
Biocross S.L. is a biotechnology-based company established in 2005 as a spin-off of the Spanish National Research Council (CSIC) with the aim of studying new biomarkers for the diagnosis of neurodegenerative diseases and developing reliable blood-based diagnostic methods applicable in hospital settings.
How does Biocross contribute to the diagnosis of Alzheimer’s disease?
We provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Our novel diagnostic approach is made possible by simultaneous analysis of a combination of distinct biomarker types.
Our test is designed to discriminate between different forms of dementia to identify and correctly classify patients with Alzheimer’s disease.
We offer cost-effective solutions that can be easily incorporated into hospital routines.
Biocross’ global solution
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96
